Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PSMA/PRAME · 1 trial · 23 indications
| Arm | Type | Description |
|---|---|---|
| Low Dose Cohort | EXPERIMENTAL | - |
| High Dose Cohort | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| PSMA/PRAME | BIOLOGICAL | Low dose |
Inclusion Criteria: 18 years of age or older Advanced, refractory solid malignancy that is histologically proven Measurable disease ECOG performance status of 0, 1 or 2 Adequate bone marrow reserve as evidenced by a Absolute neutrophil count (ANC) = 1,500/microL; Platelet count = 100,000/microL Ade...
Top 20 of 60 competitors
PSMA/PRAME is an investigational monoclonal antibody being studied for the treatment of ovarian cancer. It is currently in Phase 1 clinical development. The drug is being evaluated for its safety and immune response in patients with advanced cancer, including ovarian cancer.
PSMA/PRAME is a monoclonal antibody that targets two antigens: PSMA (prostate-specific membrane antigen) and PRAME (preferentially expressed antigen in melanoma). These targets are associated with various cancer types, and the drug is designed to elicit an immune response against cells expressing these antigens.
PSMA/PRAME is being developed by MannKind Corporation, a biopharmaceutical company. The company is listed on the stock exchange under the ticker symbol MNKD. The drug is currently in Phase 1 clinical trials for the treatment of ovarian cancer.
PSMA/PRAME is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The drug is being studied in a completed Phase 1 trial to evaluate its safety and immune response in patients with advanced cancer.
PSMA/PRAME has one completed clinical trial, identified as NCT00423254. This Phase 1 study, titled "Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer," enrolled 12 participants and included patients with ovarian cancer and other advanced solid tumors.
Yes, PSMA/PRAME is also known as MKC1106-PP. The completed Phase 1 clinical trial NCT00423254 evaluated MKC1106-PP, which is the same investigational therapy. This multi-component immune-based therapy is being developed by MannKind Corporation for advanced cancers, including ovarian cancer.